These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 22867298)

  • 1. Human Immunodeficiency Virus Gag and protease: partners in resistance.
    Fun A; Wensing AM; Verheyen J; Nijhuis M
    Retrovirology; 2012 Aug; 9():63. PubMed ID: 22867298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease-substrate coevolution in nelfinavir resistance.
    Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
    J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.
    Sutherland KA; Mbisa JL; Cane PA; Pillay D; Parry CM
    J Gen Virol; 2014 Jan; 95(Pt 1):190-200. PubMed ID: 24172906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease.
    Lee SK; Potempa M; Kolli M; Özen A; Schiffer CA; Swanstrom R
    J Biol Chem; 2012 Apr; 287(16):13279-90. PubMed ID: 22334652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
    van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
    Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
    Kolli M; Stawiski E; Chappey C; Schiffer CA
    J Virol; 2009 Nov; 83(21):11027-42. PubMed ID: 19706699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.
    Codoñer FM; Peña R; Blanch-Lombarte O; Jimenez-Moyano E; Pino M; Vollbrecht T; Clotet B; Martinez-Picado J; Draenert R; Prado JG
    Sci Rep; 2017 Jun; 7(1):3717. PubMed ID: 28623276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
    Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
    Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
    J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
    Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
    J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.
    Su CT; Koh DW; Gan SK
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31489889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag.
    Yu FH; Huang KJ; Wang CT
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31906562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.